JNJ vs PFE
Johnson & Johnson vs Pfizer Inc. · Updated Jun 29, 2026
JNJ — 13 winsPFE — 10 wins
Price Performance
JNJ +68.36%PFE +0.54%
Performance
| JNJ | PFE | |
|---|---|---|
| 1 Month | +10.23% | -8.07% |
| 3 Months | +6.56% | -12.60% |
| 6 Months | +23.89% | -3.15% |
| YTD | +23.19% | -3.23% |
| 1 Year | +67.42% | -0.68% |
| 3 Year | +46.52% | -42.34% |
| 5 Year | +71.80% | -33.66% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | +24.0% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
| PFE | -3.2% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
Valuation
| JNJ | PFE | |
|---|---|---|
| P/E Ratio | 29.47 | 18.39 |
| Forward P/E | 11.17 | 9.08 |
| PEG Ratio | 2.75 | -3.95 |
| P/S Ratio | 5.78 | 2.26 |
| P/B Ratio | 6.86 | 1.59 |
| EV/EBITDA | 19.30 | 12.01 |
Financials
| JNJ | PFE | |
|---|---|---|
| EPS (TTM) | $8.65 | $1.31 |
| Gross Margin | +71.49% | +67.26% |
| Operating Margin | +26.58% | +27.90% |
| Net Margin | +21.76% | +18.60% |
| ROE | +25.92% | +8.31% |
| ROA | +10.47% | +3.61% |
| Debt/Equity | 0.22 | 0.72 |
Growth
| JNJ | PFE | |
|---|---|---|
| Revenue Growth YoY | +9.91% | +5.37% |
| Revenue Growth QoQ | -2.04% | -17.69% |
| EPS Growth YoY | -52.86% | -9.55% |
| EPS Growth QoQ | +1.90% | +262.07% |
Technical
| JNJ | PFE | |
|---|---|---|
| RSI (14) | 71.11 | 36.61 |
| % From 20-Day SMA | +8.79% | -5.27% |
| % From 50-Day SMA | +10.53% | -7.20% |
| % From 200-Day SMA | +17.30% | -6.85% |
| % From 52-Week High | -0.06% | -16.18% |
| % From 52-Week Low | +68.83% | +4.26% |
Analyst Ratings
JNJ
Buy(24 analysts)
Strong SellHoldStrong Buy
Price Target
$253.42
-0.60% upside
PFE
Hold(12 analysts)
Strong SellHoldStrong Buy
Price Target
$26.75
+11.02% upside
Overview
| JNJ | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $556.76B | $142.94B |
| Shares Outstanding | 2.41B | 5.70B |
| Avg Volume (10D) | 10.44M | 57.38M |
| Dividend Yield | 2.27% | 6.86% |
Frequently Asked Questions
Is JNJ or PFE a better buy right now?
Based on 23 comparable metrics, JNJ leads in 13 categories while PFE leads in 10. JNJ has a consensus analyst rating with 24 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, JNJ or PFE?
Over the past year, JNJ returned +67.42% compared to PFE's -0.68%. In the short term (1 month), JNJ returned +10.23% vs PFE's -8.07%.
Is JNJ or PFE more expensive?
JNJ trades at a P/E of 29.47 compared to PFE's 18.39. On a price-to-sales basis, JNJ trades at 5.78x vs PFE's 2.26x. Forward P/E: JNJ at 11.17 vs PFE at 9.08.
Which stock has higher growth, JNJ or PFE?
JNJ's revenue grew +9.91% year-over-year compared to PFE's +5.37%. EPS growth: JNJ at -52.86% vs PFE at -9.55%.
Do JNJ and PFE pay dividends?
JNJ pays a dividend with a yield of 2.27%. PFE pays a dividend with a yield of 6.86%.
Which stock do analysts prefer, JNJ or PFE?
JNJ has 24 analysts with a target price of $253.42 (-0.60% upside). PFE has 12 analysts with a target of $26.75 (+11.02% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.